Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

80.63USD
26 May 2017
Change (% chg)

$-0.72 (-0.89%)
Prev Close
$81.35
Open
$80.86
Day's High
$81.02
Day's Low
$80.57
Volume
1,735,434
Avg. Vol
2,872,577
52-wk High
$83.58
52-wk Low
$66.93

NVS

Chart for NVS

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $211,456.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.72
Yield (%): 3.37

Financials

  NVS Industry Sector
P/E (TTM): 30.35 14.27 17.41
EPS (TTM): 2.66 -- --
ROI: 6.05 -7.17 -5.42
ROE: 9.13 -6.63 -4.68

BRIEF-Novartis' Zykadia wins FDA approval as initial therapy for type of lung cancer

* Novartis receives FDA approval for expanded use of zykadia® in first-line alk-positive metastatic non-small cell lung cancer (nsclc) Source text for Eikon: Further company coverage:

May 26 2017

Austria's BAWAG PSK plans to buy Germany's Suedwestbank

ZURICH, May 24 BAWAG PSK, the Austrian bank owned by private equity group Cerberus Capital Management, is in advanced talks to buy German regional lender Suedwestbank to expand its network in western Europe, BAWAG said on Wednesday.

May 24 2017

BRIEF-Novartis says analyses reinforce potential of Ultibro Breezhaler for COPD patients

* Novartis' new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

May 23 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

CHMP backs Novartis's Zykadia for first-line use in lung cancer

ZURICH, May 19 Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

May 19 2017

Novartis to cut around 500 jobs in Switzerland, add 350

ZURICH Novartis plans to cut or transfer around 500 traditional production and development jobs at Swiss sites over the next 18 months and add 350 others, mostly in its biotech business, the drugmaker said on Thursday.

May 18 2017

Novartis to cut around 500 jobs in Switzerland, add 350

ZURICH Novartis plans to cut or transfer around 500 traditional production and development jobs at Swiss sites over the next 18 months and add 350 others, mostly in its biotech business, the drugmaker said on Thursday.

May 18 2017

Novartis to cut around 500 jobs in Switzerland, add 350

ZURICH, May 18 Novartis plans to cut or transfer around 500 traditional production and development jobs at Swiss sites over the next 18 months and add 350 others, mostly in its biotech business, the drugmaker said on Thursday.

May 18 2017

BRIEF-Novartis updates analyses from Kisqali pivotal late-stage trial

* Novartis -data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care- updated analyses from Kisqali pivotal phase iii monaleesa-2 trial Source text for Eikon: Further company coverage:

May 18 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.92 -0.61
Pfizer Inc. (PFE.N) $32.14 -0.02
Merck & Co., Inc. (MRK.N) $64.92 -0.12
Roche Holding Ltd. (ROG.S) CHF266.60 -0.60
Roche Holding Ltd. (RO.S) CHF267.75 +0.25
Abbott Laboratories (ABT.N) $44.71 +0.76
Sanofi SA (SASY.PA) €87.74 +0.43
AstraZeneca plc (AZN.L) 5,227.00 +18.00
GlaxoSmithKline plc (GSK.L) 1,643.50 +25.50
Eli Lilly and Co (LLY.N) $78.05 -0.29

Earnings vs. Estimates